The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did not approve its lead investigational product, Cardamyst. The nasal spray ...

Joe Oliveto, President and CEO of Milestone Pharmaceuticals, expressed disappointment over the CRL but reaffirmed the company’s commitment to CARDAMYST as a potential novel treatment for ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...

"We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer ...

Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray ...

“2025 is set to be a transformative year for Milestone as we prepare for potential FDA approval of CARDAMYST and the opportunity to empower patients suffering with PSVT to self-manage episodes ...

The facility changed ownership during the review of the NDA. "We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help ...

"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided ...